The Filing Desk

Kiniksa Pharmaceuticals vs Pacira BioSciences

Kiniksa Pharmaceuticals KNSA · Pacira BioSciences PCRX · Pharmaceuticals

Pacira BioSciences reported revenue of $726 million in fiscal 2025, about the same as Kiniksa Pharmaceuticals' $678 million in fiscal 2025. Kiniksa Pharmaceuticals' revenue grew 60.1% in its latest year, and Pacira BioSciences' grew 3.6%. Kiniksa Pharmaceuticals had an operating margin of 11.4%, against 2.6% at Pacira BioSciences. Free cash flow was $136 million at Kiniksa Pharmaceuticals and $137 million at Pacira BioSciences.

Side by side

Kiniksa PharmaceuticalsPacira BioSciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$678M$726M
Revenue growth60.1%3.6%
Revenue growth a year, last 5 years—11.1%
Gross margin88.5%79.4%
Operating margin11.4%2.6%
Net margin8.7%1.0%
Free cash flow$136M$137M
Free cash flow margin20.1%18.8%
Return on capital—1.1%
Net debt to EBITDA—1.2x
Dividends and buybacks$0M$148M
Change in diluted share count10.6%−2.6%
Last close$96.33$36.46
P/E at the last close73.5×39.2×
Insider trades, last 12 monthssold $45.1 millionsold $2.3 million
Piotroski F-score—9 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Kiniksa PharmaceuticalsPacira BioSciences
Operating margin
Percent of revenue
Kiniksa PharmaceuticalsPacira BioSciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kiniksa PharmaceuticalsPacira BioSciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kiniksa Pharmaceuticals and Pacira BioSciences pages.